Its core advantages lie in comprehensive and potent efficacy, outstanding intracranial activity, broad anti-resistance coverage, superior safety profile, and high accessibility.
Authentic
Guarantee
Fast Delivery
Privacy Yes, Furmonertinib is a targeted therapy drug, classified as a third-generation EGFR-TKI. It can specifically inhibit EGFR gene mutations (such as T79···【Read More】
Update: 30 Jan,2026Source: Haiou HealthViews: 74
The price of Furmonertinib is affected by factors such as drug specifications, regional disparities, and medical insurance policies, with the cost per···【Read More】
Update: 30 Jan,2026Source: Haiou HealthViews: 80
The recommended oral dose of Furmonertinib is 80 mg once daily, and it can be taken either on an empty stomach or with food.【Read More】
Update: 30 Jan,2026Source: Haiou HealthViews: 74
Furmonertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), primarily indicated for the treatment of ···【Read More】
Update: 30 Jan,2026Source: Haiou HealthViews: 83
Copyright 2024 @ haiouhealth.com All right reserved SEAGULL HEALTH



